Ken Griffin Biotechnology

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Stock List

Stock Option Type Value Options Held Last Trade Trade History
ARCT
Arcturus Therapeutics Holdings Inc.
CALL
$830,000
35.8K
Q3 2024
Added 250.66%
DYN
Dyne Therapeutics, Inc.
CALL
$743,000
20.7K
Q3 2024
Reduced 31.9%
SNDX
Syndax Pharmaceuticals Inc
CALL
$731,000
38K
Q3 2024
Reduced 82.09%
ARWR
Arrowhead Pharmaceuticals, Inc.
CALL
$722,000
37.3K
Q3 2024
Added 24.16%
FULC
Fulcrum Therapeutics, Inc.
PUT
$721,000
202K
Q3 2024
Reduced 24.1%
EYPT
Eye Point Pharmaceuticals, Inc.
CALL
$720,000
90.2K
Q3 2024
Added 3.9%
KYMR
Kymera Therapeutics, Inc.
PUT
$719,000
15.2K
Q3 2024
Reduced 60.09%
HRMY
Harmony Biosciences Holdings, Inc.
PUT
$711,000
17.8K
Q3 2024
Reduced 77.4%
IMTX
Immatics N.V.
CALL
$701,000
61.5K
Q3 2024
Added 116.94%
FULC
Fulcrum Therapeutics, Inc.
CALL
$696,000
195K
Q3 2024
Reduced 24.1%
CGEM
Cullinan Oncology, Inc.
CALL
$679,000
40.6K
Q3 2024
Added 0.62%
AGIO
Agios Pharmaceuticals, Inc.
PUT
$670,000
15.1K
Q3 2024
Reduced 90.52%
MLTX
Moon Lake Immunotherapeutics
CALL
$665,000
13.2K
Q3 2024
Added 2.53%
PLRX
Pliant Therapeutics, Inc.
PUT
$662,000
59.1K
Q3 2024
Reduced 91.86%
XENE
Xenon Pharmaceuticals Inc.
CALL
$661,000
16.8K
Q3 2024
Reduced 6.01%
KMPH
Kempharm, Inc
CALL
$659,000
134K
Q3 2024
Reduced 35.47%
ARVN
Arvinas, Inc.
CALL
$657,000
26.7K
Q3 2024
Added 2.58%
KROS
Keros Therapeutics, Inc.
CALL
$656,000
11.3K
Q3 2024
Added 71.73%
RYTM
Rhythm Pharmaceuticals, Inc.
PUT
$654,000
12.5K
Q3 2024
New holding
LGND
Ligand Pharmaceuticals Inc
PUT
$651,000
6.5K
Q3 2024
Reduced 48.02%
MNKD
Mannkind Corp
CALL
$641,000
102K
Q3 2024
Reduced 33.6%
VRDN
Viridian Therapeutics, Inc.\De
CALL
$641,000
28.2K
Q3 2024
Added 440.1%
URGN
Uro Gen Pharma Ltd.
PUT
$624,000
49.2K
Q3 2024
Added 225.52%
IBRX
Immunity Bio, Inc.
CALL
$601,000
162K
Q3 2024
Added 45.69%
ROIV
Roivant Sciences Ltd.
CALL
$597,000
51.8K
Q3 2024
Added 208.11%
CADL
Candel Therapeutics, Inc.
CALL
$589,000
85K
Q3 2024
New holding
IMCR
Immunocore Holdings PLC
PUT
$582,000
18.7K
Q3 2024
Reduced 74.18%
ETNB
89bio, Inc.
PUT
$569,000
76.9K
Q3 2024
Added 21.22%
VERV
Verve Therapeutics, Inc.
PUT
$566,000
117K
Q3 2024
Added 46.85%
AGIO
Agios Pharmaceuticals, Inc.
CALL
$564,000
12.7K
Q3 2024
Reduced 90.52%
IMNM
Immunome Inc.
CALL
$557,000
38.1K
Q2 2024
New holding
PTCT
Ptc Therapeutics, Inc.
CALL
$549,000
14.8K
Q3 2024
Reduced 11.46%
PRTA
Prothena Corp Public LTD CO
PUT
$532,000
31.8K
Q3 2024
Reduced 32.7%
PTGX
Protagonist Therapeutics, Inc
PUT
$530,000
11.8K
Q3 2024
New holding
MLTX
Moon Lake Immunotherapeutics
PUT
$529,000
10.5K
Q3 2024
Added 2.53%
AMLX
Amylyx Pharmaceuticals, Inc.
PUT
$520,000
161K
Q3 2024
Added 41.25%
FOLD
Amicus Therapeutics, Inc.
CALL
$519,000
48.6K
Q3 2024
Added 20.33%
TYRA
Tyra Biosciences, Inc.
CALL
$507,000
21.6K
Q3 2024
New holding
ALDX
Aldeyra Therapeutics, Inc.
CALL
$494,000
91.7K
Q3 2024
Added 466.2%
TARS
Tarsus Pharmaceuticals, Inc.
CALL
$486,000
14.8K
Q3 2024
Added 85.3%
CCCC
C4 Therapeutics, Inc.
CALL
$485,000
85.1K
Q3 2024
Reduced 90.87%
RVMD
Revolution Medicines, Inc.
CALL
$484,000
10.7K
Q3 2024
Reduced 31.28%
DYN
Dyne Therapeutics, Inc.
PUT
$477,000
13.3K
Q3 2024
Reduced 31.9%
CGEM
Cullinan Oncology, Inc.
PUT
$475,000
28.4K
Q3 2024
Added 0.62%
CNTA
Centessa Pharmaceuticals PLC
PUT
$471,000
29.5K
Q3 2024
Added 1434.95%
ACAD
Acadia Pharmaceuticals Inc
PUT
$470,000
30.6K
Q3 2024
Reduced 74.37%
MREO
Mereo Biopharma Group PLC
PUT
$466,000
114K
Q3 2024
Reduced 68.15%
LBPH
Longboard Pharmaceuticals, Inc.
PUT
$463,000
13.9K
Q1 2024
New holding
VRNA
Verona Pharma PLC
CALL
$463,000
16.1K
Q3 2024
Added 1048.0%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email